Abstract

Since long it has been postulated that various ADRs have some genetic determinants.To the date various genes have been identified and studied. Presence of particular gene determines individual susceptibility for adverse drug reaction for a particular drug. Genome-wide association studies and HLA genotyping have detected novel associations for serious, idiosyncratic and adverse drug reactions. This review article highlights genes involved in serious adverse drug reactions for drugs which are widely prescribed and occasionally give rise to serious ADR and newly licenced drugs or drugs still in development with liability to give rise to serious ADR as detected during clinical trials based on genome wide association studies, candidate gene analysis and HLA genotyping. Pharmacogenomics haspotential role in reducing the incidence of ADRs. Targeting susceptiblegenes may potentially allow for reintroduction of some valuable drugs that have been withdrawn previously and may also help to avoid some of the serious adverse drug reactions seen with licenced drugs.

Authors and Affiliations